Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by prophetoffactzon Feb 26, 2024 12:51pm
41 Views
Post# 35899413

RE:RE:Copilot: potential benefits of avenanthramide

RE:RE:Copilot: potential benefits of avenanthramide We've never seen preclinical data for the avenanthramide pill or in combination with a newer generation PGX carrier. That shows how much hidden value there could be in this program.

prophetoffactz wrote: "The safety and bioavailability study will evaluate avenanthramides as a stand-alone therapy or potentially in combination with carriers recently developed using our PGX technology to address some inflammation-based diseases, which we believe shows great promise.” Aug. 4, 2020

We've never seen promising data combining CZO's avenanthramide with a newer generation PGX carrier. That's top secret and Gilles is a man with a long-term plan with Ronnie Miller by his side and "thrilled". The merger with AEZS and clinical trial results with the pill could allow next-gen formulation of avenanthramide with PGX to move forward further strengthening the scientific claims in large markets.  


<< Previous
Bullboard Posts
Next >>